Regulatory T cells: What the 2025 Nobel Prize in Medicine means for autoimmune diseases
Maybe you are wondering why your own immune system is attacking you and whether there is any real solution out there. This article is about a discovery that was awarded the Nobel Prize in Medicine in 2025. Researchers have found cells that can calm your immune system without switching it off completely. You will learn how these cells work, which therapies are currently being tested and whether they might one day help you.
Reading |
Imagine your body had an inner police force, a power that makes sure the fighters of your immune system do not confuse friend and foe. This power really exists. And in 2025 three researchers were awarded the Nobel Prize in Medicine for their groundbreaking discovery.
Shimon Sakaguchi, Mary E. Brunkow and Fred Ramsdell show how the immune system brakes itself
The Nobel Prize was awarded to Shimon Sakaguchi, Mary E. Brunkow and Fred Ramsdell for their discoveries on peripheral immune tolerance and the central role of regulatory T cells.
If you live with an autoimmune disease, you should know these three names. Their research might one day explain why your body attacks itself and maybe even show how that attack can be stopped.
The central puzzle of immunology: Why does our immune system not destroy our own body?
For a long time this was one of the biggest puzzles in immunology. If our immune system is strong enough to fight viruses, bacteria and even cancer, why does it not constantly attack our own body. In theory, that is exactly what should happen.
And yet this internal self protection works very reliably in most people. Until it stops working. In people with autoimmune diseases the immune system suddenly starts to attack the body’s own cells, and until a few years ago medicine did not really know why. The answer was hidden in cells that had been overlooked for a long time.
1995: Shimon Sakaguchi discovers regulatory T cells
In 1995 the Japanese immunologist Shimon Sakaguchi was observing immune cells under the microscope in his lab. He made a groundbreaking discovery. He identified a previously unknown class of T cells that actively protects the body from an overreaction of its own immune system.
Until then science had assumed that the body protects itself from self attack only in the thymus, a kind of “training school” for T cells, by eliminating potentially dangerous cells early on.
Sakaguchi showed that there are also special T cells that act like internal referees. These so called regulatory T cells, or Tregs, actively intervene and prevent aggressive immune cells from attacking the body’s own cells.
2001–2003: Brunkow and Ramsdell find the genetic key
In 2001 the US researchers Mary E. Brunkow and Fred Ramsdell identified the crucial gene behind regulatory T cells. They studied the lethal mouse disease called scurfy, in which the immune system is completely out of control.
The cause:
- a mutation in the Foxp3 gene. This gene is the biological blueprint for regulatory T cells. If the gene is defective, these protective “brake cells” cannot develop, the immune system loses control and starts to attack the body.
This made it clear that their discovery was the genetic foundation for everything Sakaguchi had observed.
In 2003 Sakaguchi showed experimentally that the Foxp3 gene controls the development and function of exactly those regulatory T cells he had first described in 1995.
Three researchers, two continents and one big puzzle solved.
How regulatory T cells protect the body from autoimmune reactions
Regulatory T cells are not passive referees. They are active, intelligent control mechanisms that supervise other immune cells in two ways.
How Tregs protect you:
- Direct contact
They touch overactive immune cells and signal to them “Stop. This is our own tissue, not an enemy.”- Chemical brakes
They release substances that change the environment and switch off aggressive cells.
This system is precise enough to stop problematic cells without paralysing the entire immune defence. Your body needs its aggressive cells to fight viruses and bacteria, but it also needs this brake.
New therapies: How Treg based immunotherapies could change autoimmune diseases
The discoveries of Sakaguchi, Brunkow and Ramsdell have already led to concrete new therapeutic approaches.
In autoimmune diseases: Strengthening regulatory T cells
In organ transplantation: Slowing rejection with Treg therapy
In cancer: When brake cells become a problem
What does the Nobel Prize mean for you with an autoimmune disease?
Maybe you have already received a diagnosis like MS, lupus or autoimmune hepatitis and you are wondering if there will ever be a real solution. The honest answer is not yet, but there is reason for hope. There are many clinical trials worldwide on regulatory T cells, including at leading German clinics such as the University Hospital Regensburg.
Research also shows how complex “healing” really is. It is not simply about having more or fewer Tregs. Too many can protect tumours, too few can lead to autoimmune reactions.
Why balance is crucial in the immune system.
The discoveries of Sakaguchi, Brunkow and Ramsdell make one thing clear. The immune system is not a simple system that can be “fixed” easily. It is a delicate network of opposing forces that regulate each other. Only if we understand this balance can we restore it in people with autoimmune diseases.
Conclusion
What stays with you and what could come next?
The 2025 Nobel Prize tells you one important thing. Your body is not a hopeless case, but at the centre of global research that is getting better and better at understanding why your immune system has lost its balance. The work of Sakaguchi, Brunkow and Ramsdell has made the “brake cells” of your immune system visible and has laid the foundation for therapies that do not just suppress but regulate in a targeted way.
What does that mean. There is no simple cure yet, but the map is becoming clearer. Researchers are learning how to strengthen Tregs, calm rejection reactions and at the same time avoid protecting cancer cells, in other words to work precisely on the balance your body is missing. Every study and every new Treg therapy is another step away from blind trial and error and towards targeted, personalised treatments.
And still, you are more than your immune system. Research can give you hope and maybe one day open up new options. But how you live with your illness, which people walk beside you and how you treat yourself will always be just as important.
ImmuniFriend – support that goes further
At ImmuniFriend we know that research is important, but it is not everything. Coping with an autoimmune disease in a holistic way needs more. It needs emotional support, understanding and community. Scientific breakthroughs can bring hope. But the path you walk every day is at least as important. And you do not have to walk it alone.
This is where we want to be by your side. In ImmuniFriend’s psychologist led group programmes you meet other people with autoimmune diseases who are going through similar things as you. You talk about what new therapies and studies do to you emotionally.
In our groups you will find:
You do not have to explain everything. You are allowed to just be yourself, with everything that is going on for you.
If you like: a first step
If you feel that you are currently fighting through this mostly on your own, our group might be a good place to start. You can get information without any obligation. We are happy if you join us.
👉 Here you can learn more about our group programmes
👉 Here you can sign up for our pilot programme
Disclaimer
The contents of this article are for general information about the current state of research. They are not a substitute for medical diagnosis or treatment. For any health concerns, please always consult qualified medical professionals.
Sources
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003). Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nature Immunology, 4(4), 330–336. https://doi.org/10.1038/ni904
Hori, S., Nomura, T., & Sakaguchi, S. (2003). Control of regulatory T cell development by the transcription factor Foxp3. Science, 299(5609), 1057–1061. https://doi.org/10.1126/science.1079490
Karolinska Institut (2025). The Nobel Prize in Physiology or Medicine 2025. https://www.nobelprize.org/prizes/medicine/2025/press-release/
Kämpe, O. (2025). Begründung der Nobelpreisvergabe für periphere Immuntoleranz. Nobel Committee for Physiology or Medicine, Karolinska Institute.
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995). Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. The Journal of Immunology, 155(3), 1151–1164.
Sakaguchi, S., Ono, M., Setoguchi, R., Yagi, H., Hori, S., Fehervari, Z., … & Nomura, T. (2006). Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunological Reviews, 212(1), 8–27. https://doi.org/10.1111/j.0105-2896.2006.00427.x
Sakaguchi, S. (2005). Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nature Immunology, 6(4), 345–352. https://doi.org/10.1038/ni1178
Setoguchi, R., Hori, S., Takahashi, T., & Sakaguchi, S. (2005). Homeostatic maintenance of natural Foxp3+ CD25+ CD4+ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. The Journal of Experimental Medicine, 201(5), 723–735. https://doi.org/10.1084/jem.20041982
Singh, R. P., La Cava, A., Wong, F. S., Englander, G., & Tartaglia, N. R. (2007). Molecular mimicry can account for autoreactivity and explain autoimmune disease. Nature Medicine, 12(1), 111–118. https://doi.org/10.1038/nm1391
Vignali, D. A., Collison, L. W., & Workman, C. J. (2008). How regulatory T cells work. Nature Reviews Immunology, 8(7), 523–532. https://doi.org/10.1038/nri2343
Zheng, Y., Josefowicz, S., Kas, A., Chu, T. T., Gavin, M. A., & Rudensky, A. Y. (2007). Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature, 445(7130), 931–935. https://doi.org/10.1038/nature05563